Dynavax Technologies | DVAX - Trade Debtors


Dynavax Technologies reported $73.34M in Trade Debtors for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 918.45M
Cash and Equivalent USD 99.1M
Cost of Sales USD 14.04M
Current Assets USD 785.71M
Current Liabilities USD 118.23M
Debt USD 260.51M
EBIT USD 10.86M
EBITDA USD -21.59M
Employees 405
EPS Earnings Per Share USD 0.14
Equity Capital and Reserves USD 494.16M
Gross Profit on Sales USD 78.57M
Interest Expense on Debt USD 1.64M
Interest Income USD 7.74M
Loan Capital USD 220.75M
Market Capitalization USD 1.27B
Net Income USD 18.72M
Operating Expenses USD 81.01M
Operating Profit USD 10.86M
Ordinary Share Capital USD 117.23M
PE Price to Earnings USD 47.66
Pre-Tax Profit USD 21.22M
Sales Revenues USD 95.44M
Selling and Administration Expenses USD 41.54M
Stock USD 75.69M
Trade Creditors USD 2.7M
Trade Debtors USD 73.35M

Trade Debtors Change Date
AbbVie USD 12.48B 1.56B Mar/2025
Adma Biologics USD 109.73M 59.73M Jun/2025
Amgen USD 8.7B 569M Jun/2025
AstraZeneca USD 16.24B 1.42B Jun/2025
Biogen USD 2.08B 87.5M Jun/2025
BioMarin Pharmaceutical USD 855.85M 116.68M Jun/2025
Bristol-Myers Squibb USD 15.1B 515M Jun/2025
Dynavax Technologies USD 73.34M 16.79M Jun/2025
Gilead Sciences USD 4.78B 393M Jun/2025
Glaxosmithkline GBP 7.7B 372M Jun/2025
Merck USD 12.72B 1.14B Jun/2025
Neurocrine Biosciences USD 595.7M 79.7M Jun/2025
Novartis USD 9.18B 451M Jun/2025
Pfizer USD 16.09B 1.35B Jun/2025
Regeneron Pharmaceuticals USD 5.61B 49M Jun/2025
Roche Holding CHF 13.46B 984M Dec/2024
Sarepta Therapeutics USD 609.6M 114.93M Jun/2025
TG Therapeutics USD 231.52M 102.33M Jun/2025
Vertex Pharmaceuticals USD 1.89B 88.4M Jun/2025